In a 20‑year‑old patient with known rheumatic heart disease presenting with hemoptysis and echocardiography showing severe aortic regurgitation, severe mitral regurgitation, severe tricuspid regurgitation, bi‑atrial enlargement, intermediate‑probability pulmonary hypertension, and pulmonic regurgitation, what are the three most likely causes of the hemoptysis and what is the optimal management?

Top 3 Differential Diagnoses for Hemoptysis

In this 20-year-old with severe multivalvular RHD and pulmonary hypertension, the three most likely causes of hemoptysis are: (1) pulmonary venous hypertension from severe left-sided valve disease causing alveolar capillary rupture, (2) pulmonary embolism, and (3) pulmonary tuberculosis.

Rationale for Each Differential

1. Pulmonary Venous Hypertension (Most Likely)

• The severe mitral and aortic regurgitation creates marked pulmonary venous pressurization, with intermediate-probability pulmonary hypertension already documented 1
• This patient meets Stage C/D RHD criteria with severe MR, severe AR, and pulmonary hypertension—all high-risk features for clinical complications 2
• Hemoptysis occurs in 48% of RHD patients and is usually well-tolerated, typically presenting as blood-streaked sputum from chronic venous congestion 3
• The bi-atrial enlargement and pan-valvular regurgitation indicate chronic severe volume overload driving pulmonary venous hypertension

2. Pulmonary Embolism

• Patients with severe RHD and atrial enlargement are at high risk for atrial fibrillation and thromboembolic complications 4
• Bi-atrial enlargement suggests chronic atrial stretch and potential for thrombus formation
• Stroke and peripheral embolism occur in 3.9% and 4.1% of RHD patients respectively; pulmonary embolism follows similar pathophysiology 4
• Must be actively excluded given the acute presentation and potential for catastrophic outcomes

3. Pulmonary Tuberculosis

• Critical to exclude in endemic regions, particularly given the patient's young age
• In the Ethiopian RHD cohort, 64% were tested for TB with 5 actively treated 3
• TB can coexist with RHD and present with hemoptysis
• Requires chest imaging and sputum studies for definitive exclusion

---

Optimal Management Strategy

This patient requires urgent surgical evaluation for multivalve intervention, as medical therapy alone cannot address the underlying severe valvular pathology driving the hemoptysis and clinical deterioration.

Immediate Management (First 24-48 Hours)

Diagnostic Workup

• Chest CT angiography to exclude pulmonary embolism (given acute hemoptysis presentation)
• Chest X-ray and sputum studies (AFB smear, culture, GeneXpert) to exclude tuberculosis
• ECG and continuous monitoring to detect atrial fibrillation
• Complete blood count, coagulation studies, and type and screen
• Right heart catheterization if surgical planning requires precise hemodynamic assessment

Medical Stabilization

• Diuretics for pulmonary congestion management (reduce pulmonary venous pressure) 5
• Anticoagulation if atrial fibrillation is present or pulmonary embolism confirmed—noting that only 77.7% of high-risk RHD patients receive appropriate anticoagulation 4
• Oxygen therapy to maintain adequate saturation
• Avoid pulmonary vasodilators—these worsen left heart congestion in pulmonary hypertension from mitral valve disease 1

Definitive Management

Surgical Intervention (Primary Treatment)

Multivalve surgery is the definitive treatment and should not be delayed once the patient is medically optimized. 1

Surgical Approach

• Mitral valve repair or replacement (primary driver of symptoms)
• Aortic valve replacement (severe AR requires intervention)
• Tricuspid valve annuloplasty with ring should be performed concomitantly 5, 6
  • Tricuspid annulus diameter ≥35 mm is the best criterion for performing annuloplasty 6
  • Isolated tricuspid surgery later has poor outcomes due to established RV dysfunction 6
  • Severe TR is an independent predictor of adverse outcomes (HR 2.30) and predicts poor survival 7

Critical Surgical Timing Considerations

• Surgery must occur before irreversible RV dysfunction develops 6
• The patient already has severe TR and intermediate-probability pulmonary hypertension—delaying surgery risks progression to inoperable RV failure
• Despite higher perioperative risk with pulmonary hypertension, the potential benefits justify the risks as the root cause (severe MVD) will otherwise progress 1

Why Medical Therapy Alone Fails

• Direct PH medical therapies are ineffective and may worsen left heart congestion when severe mitral/aortic disease is uncorrected 1
• Without correcting the primary valvular pathology, heart failure, PH, and RV dysfunction will inevitably progress 1
• The hemoptysis reflects advanced hemodynamic derangement that cannot resolve without valve correction

Post-Operative Management

Secondary Prevention

• Benzathine penicillin G every 3-4 weeks for secondary prophylaxis (only 28.5% of RHD patients receive this appropriately) 4
• Anticoagulation if mechanical valves implanted or atrial fibrillation persists
• Serial echocardiography to monitor for prosthetic valve function and residual TR progression 8

Long-Term Surveillance

• Monitor for TR progression—occurs at 3.7 events per 100 patient-years in RHD 7
• Predictors of TR progression include age, NYHA class III/IV, right atrial enlargement, and RV dysfunction 7
• Enrollment in RHD registry if available 2

---

Critical Pitfalls to Avoid

1. Delaying surgery for "medical optimization"—this patient is already Stage C/D RHD with complications; further delay risks irreversible RV dysfunction 2

2. Addressing only the mitral valve—failure to perform concomitant tricuspid annuloplasty leads to persistent severe TR and poor long-term outcomes 6

3. Using pulmonary vasodilators—these worsen pulmonary venous congestion in left-sided valve disease 1

4. Assuming hemoptysis is benign—while common in RHD (48% prevalence), acute presentation warrants exclusion of PE and TB 3

5. Inadequate anticoagulation—if atrial fibrillation present, only 77.7% receive appropriate therapy despite clear indication 4